| Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements. Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations. |
Softcon Systems is a leading supplier of automation solutions for the Mining, Minerals and Metals (MMM) industries, with a worldwide presence and broad application experience.
We help control operations for a wide variety of metals and minerals.
From concentration to smelting and refining, from blast furnaces to digestion, Softcon has a solution to meet all control needs whilst significantly increasing business value.
With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.
To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html Key Market Insights Over 100 CMOs presently claim to offer manufacturing services for antibodies The antibody contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders.
It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial).
Europe has emerged as a key manufacturing hub for antibody-based productsMore than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe.
Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan.
Demand for therapeutic antibodies is anticipated to grow at a CAGR of 10%, during 2020-2025Given the fact that there are a number of antibody-based products in the market, the commercial demand for antibodies is significantly higher than the clinical demand.